Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-23-003413
Filing Date
2023-05-15
Accepted
2023-05-15 12:50:43
Documents
40
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q soulbiotechno_10q.htm   iXBRL 10-Q 526183
2 EXHIBIT 31.1 soulbiotechno_ex31-1.htm EX-31.1 12788
3 EXHIBIT 32.1 soulbiotechno_ex32-1.htm EX-32.1 7535
  Complete submission text file 0001829126-23-003413.txt   2376531

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adob-20230331.xsd EX-101.SCH 17513
5 XBRL CALCULATION FILE adob-20230331_cal.xml EX-101.CAL 29403
6 XBRL DEFINITION FILE adob-20230331_def.xml EX-101.DEF 56532
7 XBRL LABEL FILE adob-20230331_lab.xml EX-101.LAB 161345
8 XBRL PRESENTATION FILE adob-20230331_pre.xml EX-101.PRE 131967
34 EXTRACTED XBRL INSTANCE DOCUMENT soulbiotechno_10q_htm.xml XML 221736
Mailing Address 36 FOURTH AVE. N SASKATCHEWAN A9 S3N 2V7
Business Address 36 FOURTH AVE. N SASKATCHEWAN A9 S3N 2V7 (516) 544-2812
Soul Biotechnology Corp (Filer) CIK: 0001726822 (see all company filings)

EIN.: 823155323 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56213 | Film No.: 23920329
SIC: 2833 Medicinal Chemicals & Botanical Products